{"article_title": "It Costs $2.6 Billion To Develop A New Medicine; 2.5 Times More Than In 2003", "article_keywords": ["billion", "25", "26", "develop", "times", "2003", "costs", "medicine"], "article_url": "http://www.forbes.com/sites/theapothecary/2014/11/26/crisis-in-pharma-rd-it-costs-2-6-billion-to-develop-a-new-medicine-2-5-times-more-than-in-2003/", "article_text": "", "article_metadata": {"prerender-status-code": "{{meta.code}}", "author": "The Apothecary", "og": {"site_name": "Forbes", "description": "The rate of growth of health spending remains moderate. One area where prices appear to be increasing faster than they have in the past few years is brand-name prescription drugs. Specialized drugs for smaller patient populations have been launched with high nominal prices. Reducing prices of specialty drugs requires improving the productivity of R&D. Rep. Fred Upton, Chair of the House Energy & Commerce Committee, has launched a bipartisan initiative for \u201c21st Century Cures\u201d that is examining the entire regulatory process governing the research enterprise. It is a necessary and welcome step in the right direction.", "title": "Crisis In Pharma R&amp;D: It Costs $2.6 Billion To Develop A New Medicine; 2.5 Times More Than In 2003", "url": "http://www.forbes.com/sites/theapothecary/2014/11/26/crisis-in-pharma-rd-it-costs-2-6-billion-to-develop-a-new-medicine-2-5-times-more-than-in-2003/", "image": "http://blogs-images.forbes.com/theapothecary/files/2014/08/670px-ritalin-sr-20mg-1000x1000.jpg", "updated_time": "2014-12-04T14:03:42-05:00", "type": "article"}, "twitter": {"description": "The rate of growth of health spending remains moderate. One area where prices appear to be increasing faster than they have in the past few years is brand-name prescription drugs. Specialized drugs for smaller patient populations have been launched with high nominal prices. Reducing prices of specialty drugs requires improving the productivity of R&D. Rep. Fred Upton, Chair of the House Energy & Commerce Committee, has launched a bipartisan initiative for \u201c21st Century Cures\u201d that is examining the entire regulatory process governing the research enterprise. It is a necessary and welcome step in the right direction.", "creator": "@forbesopinion", "image": "http://blogs-images.forbes.com/theapothecary/files/2014/08/670px-ritalin-sr-20mg-1000x1000.jpg", "title": "Crisis In Pharma R&amp;D: It Costs $2.6 Billion To Develop A New Medicine; 2.5 Times More Than In 2003", "site": "@forbes", "card": "summary_large_image"}, "apple-itunes-app": "app-id=588647136", "fb": {"app_id": 123694841080850}, "keywords": "Healthcare  Fiscal,OpEd,Healthcare &amp; Fiscal,Op/Ed", "article": {"publisher": "https://www.facebook.com/forbes", "author": "http://www.facebook.com/https://www.facebook.com/forbesaroy", "section_url": "http://www.forbes.com/opinion", "section": "Opinion", "modified": "2014-12-04", "published": "2014-11-26", "id": "blogAndPostId/blog/post/1314-22791"}, "news_keywords": "Healthcare  Fiscal,OpEd,Healthcare &amp; Fiscal,Op/Ed", "viewport": "width=device-width,initial-scale=1,maximum-scale=1,user-scalable=no", "description": "The rate of growth of health spending remains moderate. One area where prices appear to be increasing faster than they have in the past few years is brand-name prescription drugs. Specialized drugs for smaller patient populations have been launched with high nominal prices. Reducing prices of specialty drugs requires improving the productivity of R&D. Rep. Fred Upton, Chair of the House Energy & Commerce Committee, has launched a bipartisan initiative for \u201c21st Century Cures\u201d that is examining the entire regulatory process governing the research enterprise. It is a necessary and welcome step in the right direction."}, "_id": "\"57477af46914bd0286fd8c03\"", "article_summary": ""}